Growth Metrics

AbCellera Biologics (ABCL) Change in Taxes (2021 - 2026)

AbCellera Biologics filings provide 6 years of Change in Taxes readings, the most recent being -$5.0 million for Q1 2026.

  • Quarterly Change in Taxes fell 12.75% to -$5.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$30.4 million through Mar 2026, down 660.46% year-over-year, with the annual reading at -$29.8 million for FY2025, 548.7% down from the prior year.
  • Change in Taxes hit -$5.0 million in Q1 2026 for AbCellera Biologics, up from -$10.1 million in the prior quarter.
  • Across five years, Change in Taxes topped out at $70.0 million in Q1 2022 and bottomed at -$87.2 million in Q3 2022.
  • Average Change in Taxes over 5 years is -$5.1 million, with a median of -$3.2 million recorded in 2024.
  • Peak annual rise in Change in Taxes hit 1242.66% in 2022, while the deepest fall reached 11467.01% in 2022.
  • AbCellera Biologics' Change in Taxes stood at -$53.7 million in 2022, then soared by 103.31% to $1.8 million in 2023, then skyrocketed by 763.41% to $15.4 million in 2024, then crashed by 165.44% to -$10.1 million in 2025, then soared by 50.55% to -$5.0 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Change in Taxes are -$5.0 million (Q1 2026), -$10.1 million (Q4 2025), and -$12.2 million (Q3 2025).